Abstract: A limb support system for an operating table or hospital bed is provided and includes an adjustable member configured to be connected to a limb support associated with an operating table or hospital bed, where, in use, the system is configured to allow the adjustment member and an attached limb support to extend outwardly from the operating table or hospital bed when required, and allow the adjustment member and the limb support to be located under the operating table or hospital bed when not required.

Abstract: A multi-functional curved board used as a support for legs of a user and for general maintenance of muscle strength, the multi-functional curved board having one or more curved bodies (1) including a radius of curvature, a longitudinal axis, and at least one raised foot support. The multi-functional curved board can be bent in the direction transverse to the radius of curvature to enable the multi-functional curved board to rotate around the longitudinal axis.

Abstract: This describes a treatment method for autism/ASD intended to encourage greater eye contact by affected children. The treatment method incorporates an artificial demonstration of the phenomenon of eye contact, and that method is described herein along with the principles of action of the treatment and the necessary procedure to perform it. Also described are two embodiments of the physical portion of the invention that can be used for the demonstration: first, an item in the form of a cuboid with animatronic eyes affixed to one side that most purely reflects the principles behind the treatment, and second, another in the form of a stuffed toy that is perhaps more practical.

Abstract: A traction device has a frame, a first bladder portion, a second bladder portion, and a third inflatable bladder portion. The first bladder expands in an outward direction a distance greater than in a transverse direction. The second bladder expands in a first angular direction. The second bladder is positioned generally inferior to and to the side of the first bladder. The third bladder expands in a second angular direction. Upon expanding in the outward direction, the first bladder bears against the back of the user's neck. Upon expanding in the transverse direction, the first bladder applies an angular traction to the cervical spine. Upon expanding in the first angular direction, the second bladder bears angularly against the back of the user's upper thoracic region. Upon expanding in the third angular direction, the third bladder bears angularly against the user's occiput.

Abstract: An oral appliance for use with a subject in his/her mouth includes a flexible tube having an input end and an output end and an electrode coupled to the flexible tube adjacent the output end. The flexible tube is adapted to be positioned in the subject's oral cavity with the output end positioned in a posterior region of the oral cavity. The electrode is adapted and configured to administer an electrical stimulation to the posterior region of the oral cavity. An electrode lead is disposed within the flexible tube and connected to the electrode. An electrical stimulation control unit is connected to the electrode lead. A method of administering an electrical stimulation to a posterior region of an oral cavity of a subject is also provided.

Abstract: A device for use in physical therapy is provided. The device includes an axis, and a plurality of balls which are rotatably mounted on the axis. Each ball is equipped with a shaft through which the axis extends. The surface of the shaft is equipped with a plurality of spaced apart protrusions, and an adjustable locking feature disposed on the axis that rotatably and releasably engages the grooves formed by the spaces between the protrusions such that the distance between the balls may be adjustably fixed to any of a plurality of predetermined values.

Abstract: A vibrator apparatus includes a moving coil, which is rigidly attached to a member, e.g. a frame or beam, of a vibration device. The moving coil is for an elected vibration mode of the apparatus configured to receiving electric signals, e.g. pulsating and/or sinusoidal electric signals, from a signal unit. The moving coil co-operates with a permanent magnet, which is suspended by springs attached to the member, and the coil and the magnet are mutually linearly and coaxially movable upon application of electric signals to the moving coil. An actual distance of movement being part of a distance between extreme positions and being less than the axial length of the moving coil. The springs are located at a distance from a respective axial end portion of the permanent magnet.

Abstract: Systems and methods for providing network connectivity and remote monitoring, optimization, and control of pool/spa equipment are provided. “Internet-of-Things” (IoT) functionality is provided for pool and spa equipment in a flexible and cost-effective manner. Network connectivity and remote monitoring/control of pool and spa equipment is provided by various components such as a network communication and local control subsystem installed in pool/spa equipment, and other components. Also disclosed are various control processes (“pool logic”) which can be embodied as software code installed in any of the various embodiments of the present disclosure.

Abstract: A headache-relieving device is provided including a device body having a first side, a second side and, preferably, a connecting portion connecting the second side to the first side. A hand space is formed between the first side and the second side allowing a user to insert his or her hand. A pressing element is provided on the second side. The pressing element is configured to apply pressure against a pressure point of a user's hand positioned in the hand space. The device provides an effective, drug-free and risk-free headache relieving device which is easy to carry and store, and can be conveniently and easily turned to in the event of a headache.

Abstract: A syringe adapter is used for connecting a dosing syringe to a container in order to take up a fluid. The syringe adapter has a fluid delivery channel for creating a flow connection between the inside of the container and the inside of the dosing syringe. At least one ventilation channel of the syringe adapter is used for creating an air connection between the inside of the container and the container surroundings. In at least one of the channels a non-return valve is arranged, which allows the passage of media in an open position and in a closed position closes the channel. This results in a syringe adapter which has improved handing and in particular provides sufficient dosing precision.

Abstract: A tablet splitting apparatus includes a guide, a catcher, and a splitting mechanism. The splitting mechanism comprises a pair of blades and a pair of blade shifters. The guide, the catcher, and the splitting mechanism are accommodated in a housing. The housing includes an opening and a support. The support and the guide each include a sliding portion. The guide disposed at the supporting position is slid along the sliding portion of the support so as to be detachable from the supporting position through the opening. The blades and the blade shifters each comprise a sliding portion. The blades and the blade shifters are in a slidable contact with each other at the sliding portions. The blades attached to the respective predetermined positions of the blade shifters are slid along the sliding portions of the blade shifters so as to be detachable from the blade shifters through the opening.

Abstract: In one aspect, the present invention is directed to a baby bottle apparatus, comprising: a nipple (11); a liquid container (12); a flexible tube (17) connecting the nipple to the container; a normally-closed valve, for controlling the flow of fluid from the container (12) to the nipple (11); at least one lever (13), for opening the valve for fluid passage from the container to the nipple; thereby allowing a user to control fluid flow from the baby bottle apparatus. Preferably, the mechanism for limiting the distance between the parallel bars comprising a rotatable ring (15) having a different outer diameter therealong, such that a movement of each of the levers (13) is limited by the ring (15).

Abstract: The present invention relates to a polymerization catalyst having storage stability under an oral cavity environment. Furthermore, the present invention relates to a dental material cured by use of the present polymerization catalyst. The polymerization catalyst for use in the dental material is achieved with including 1-cyclohexyl-5-propylbarbituric acid and trioctylmethylammonium chloride.

Abstract: A wet wipe useful for removing soot and other potentially dangerous carcinogens from skin surfaces is comprised of a primarily aqueous solution with additional ingredients effective in washing away, rather than embedding, soot and carcinogens in the skin.

Abstract: Zinc oxide coated with silicon oxide of the present invention is zinc oxide which is coated with silicon oxide wherein surfaces of zinc oxide particles are coated with silicon oxide coatings, and the coated zinc oxide particles comprises at least one element selected from a group consisting of Mg, Ca, and Ba.

Abstract: A delayed release delivery system comprises a hydrophilic core particle having surface pores and containing a liquid. The particle is encapsulated in a polymer having a hydrophobic backbone and hydrophilic pendant groups. At least some of the surface pores adjacent the hydrophilic pendant groups are blocked in the presence of water and unblocked in the absence of water. The treated particle contains liquid in a weight ratio of the liquid to the porous core particle of at least 400:1.

Abstract: Provided is an oral care composition, e.g., a dentifrice, comprising a calcium abrasive, e.g., calcium carbonate, potassium nitrate (KNO3), and a basic amino acid, in free or salt form, e.g., arginine, in free or salt form, wherein the potassium nitrate is present in an amount of 0.1-1% by weight of the composition and methods of using the same.

Abstract: Certain dermatological formulations for direct skin application that correct for hyperpigmentation effects are provided. Such formulations include a number of different compounds that work synergistically to effectuate multiple and varied pathways to pigment removal and/or brightening within the dermal layer. The ability to do so without the necessity for hydroquinone, and thus with a suitable composition that is safe for handling and utilization by pregnant and nursing women, is accorded through a combination of specific ingredients in limited proportional ranges, as well. Such ingredients include kojic acid, niacinamide, sodium hyaluraonate, tocopherol, and licorice extract in very narrow ranges proportionally within an aqueous serum. The method of manufacture and use thereof such formulations are encompassed within the invention as well.

Abstract: The present disclosure relates to compositions and methods for improving the quality and durability of color in artificially colored hair. The methods employ pre-color treatments containing divalent metal salts of inorganic acids and monovalent or divalent metal salts of organic acids (treatments to the hair prior to artificial coloring of hair) and optionally, post-color treatments containing silane compounds (treatments to the hair after artificial coloring of hair).

Abstract: Disclosed is a cosmetic composition comprising particles dispersed in a cosmetically acceptable carrier, wherein the particles comprise redox dye and reducing agent.

Abstract: Described herein are oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with particular co-polymers as additional excipients; including some embodiments which further comprise a calcium abrasive.

Abstract: Embodiments of a hair conditioning composition include a silicone polymer comprising one or more quaternary groups, at least one silicone block comprising greater than 200 siloxane units, at least one polyalkylene oxide structural unit, and at least one terminal ester group. The silicone polymer has a viscosity of up to 100,000 mPa·s. The silicone polymer is added to create a pre-emulsified dispersion with a particle size of less than about 1 micron. The hair conditioning composition includes a gel matrix including a cationic surfactant, a high melting point fatty compound, and an aqueous carrier.

Abstract: An Aesculus hippocastanum extract able to be obtained by an extraction method comprising a solid/liquid extraction step of the flower, followed by a second solid/liquid separation step, and lastly a third step for recovering the liquid phase, characterized in that the solvent consists of a mixture of fructose and glycerin optionally comprising water.

Abstract: The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing an anti-C. jejuni immune response.

Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Abstract: An improved polymer delivery system is described which provides polymeric microparticle compositions and porous microparticles formed therefrom. Pore size, pore architecture as well as particle size are also controllable. In some embodiments, both the polymeric microparticle compositions and porous microparticles formed therefrom encapsulate at least one substance, such as a biologic substance (one having biologic activity and/or compatible with a biologic system). The encapsulation occurs prior to polymerization. The amount of substance that is encapsulated may be controlled by the described methods. Said methods do not emply organic solvents. As such, the fabrication occurs in a solvent-free system.

Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Abstract: The present invention relates to nano-liposome carrier compositions that encapsulate a hybrid of a Cas9 protein and a guide RNA and methods of making and using the same. The nano-liposome carrier compositions have an excellent effect of suppressing expression of target DNA, and thus pharmaceutical compositions including the nano-liposome carrier compositions can be used for treating diseases such as diabetes.

Abstract: A method of preparing probiotic nanoparticles can include dissolving formulated probiotics in methanol, spraying the methanol solution into boiling water under ultrasonic conditions to provide a sonicated solution, and stirring the sonicated solution to obtain probiotic nanoparticles. The probiotic nanoparticles may be cluster or rod-shaped. The probiotic nanoparticles may be administered to a subject to reduce oxidative stress or to treat diseases associated with oxidative stress.

Abstract: The present invention belongs to the field of bio-pharmaceutical material preparation technology, and relates to a preparation method of albumin nanoparticle carrier entrapping taxane-typed drug. This preparation method rapidly forms nanoparticle solution of albumin entrapping taxane-typed drug under room temperature by adding solvent as the medium. Next, by the second time of freeze-drying, stable powder of albumin nanoparticles entrapping taxane-typed drug is obtained. The final freeze-dried powder only includes two components: albumin and taxane-typed drug. The particles are in regular spherical shape, and the diameter of particle is less than 100 nm. The present invention has high drug loading ratio and entrapment efficiency. The experiment of releasing in vitro shows that the present invention has a good slow-release effect. Taxane-typed drug nanoparticles provided by the present invention improves the safety and compliance of this type of reagent.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: A solid pharmaceutical dosage form has micro- or nanostructures impressed on the surface thereof or an interface thereof. The dosage form includes a suitable quantity and distribution of ingredients, such as one or more dyes, so as to enhance the optical contrast effect caused by the micro- or nanostructures so that the micro- or nanostructures are observable by the human eye and thereby able to provide anti-counterfeiting characteristics to the dosage form.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: An encapsulation of deer velvet powder for ensuring delivery of the deer velvet powder to the terminal ileum of the small intestine, thereby ensuring micellization of unaltered molecules of the deer velvet powder, and systemic delivery of the unaltered molecules to all the organs of the body for regeneration and repair. The encapsulation includes: a delayed release capsule, and deer velvet powder contained within the delayed release capsule. The delayed release capsule is acid resistant, thereby protecting the deer velvet powder from digestive processes while transiting the stomach and upper small intestine, enabling the deer velvet powder to be released substantially along the terminal ilium of the small intestine so as to ensure micellization and absorption of unaltered molecules of deer velvet. Thus, swallowing the deer velvet powder encapsulated in a delayed release capsule delivers more of the benefits of deer velvet than standard encapsulations of deer velvet.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: A non-bleeding curcumin (NBC) which eliminate the problems of color bleeding, color leaching, color staining and dusting during the industrial processing of curcumin and its methods of preparation is disclosed in the invention. The invention also provides a water based process of preparation of food grade non-bleeding curcumin which is free of synthetic excipients.

Abstract: Disclosed herein is a platelet membrane-coated nanovehicle having an inner core comprising a drug delivery matrix, and an outer shell platelet membrane coating the inner core. The inner core can be any drug delivery matrix capable of delivering a therapeutic agent to a cell. The outer shell platelet membrane can be a natural or synthetic membrane comprising platelet proteins capable of interacting with cancer cells. Also disclosed is a method for treating cancer in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein. Also disclosed is a method for treating vascular disease in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein.

Abstract: The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided.

Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Abstract: The instant invention provides methods and compositions for the treatment and prevention of cell proliferative disorders.

Abstract: Derivatives of 6-shogaol are described herein. Also described herein are methods of preparing the derivatives, as well as methods of using the derivatives to activate Nrf2 and to treat diseases associated with inflammation and/or oxidative stress.

Abstract: A method of treating an ocular disorder in a subject associated with increased all-trans-retinal in an ocular tissue includes administering to the subject a therapeutically effective amount of a primary amine compound of formula (I); and pharmaceutically acceptable salts thereof.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: A ruminant feed composition, having a granulated core having at least one active substance and at least one layer of a coating material surrounding the core, the coating material comprising one or more linear, saturated aliphatic monocarboxylic acids in an amount of at least 60 wt % of the total weight of the coating material.

Abstract: Provided is an antihypertensive agent that is safe and has a mild effect. An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.

Abstract: The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing fibrosis in a subject in need thereof.

Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.

Abstract: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.

Abstract: Implantable medical devices and methods are provided that have one or more statins disposed therein. The medical devices may be implanted at near or in a bone defect to enhance bone growth. In some embodiments, the medical device provided allows for sustain release of the statin and facilitates bone formation and repair of the fracture site.

Abstract: A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 ?M concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.